SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC

Summary

This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) and has been receiving treatment with Osimertinib

Timeline

Start

2023-01-01

Primary completion

2024-12-30

Completion

2025-12-30

Drugs

Indications